This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Withdrawal Reactions Associated With Low-Dose Venlafaxine Treatment in a Patient With Premenstrual Dysphoric Disorder

Mei-Chun Hsiao, MD; Chia-Yih Liu, MD

Published: August 16, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: It has recently been demonstrated that venlafaxine, a serotonin-norepinephrine reuptake inhibitor, is effective for the treatment of premenstrual dysphoric disorder (PMDD).1,2 However, withdrawal reactions with venlafaxine have been reported. 3-7 Most of these withdrawal reactions were noted in patients with depressive disorder and associated with daily venlafaxine doses of 150 mg or more


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Depression (MDD) , Premenstrual Dysphoric Disorder

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...